Novo Nordisk spotlights future innovations within diabetes as insulin sales recede
Novo Nordisk has two types of insulin in the works which would finally bring some much-needed innovation to the area, says Novo exec Camilla Sylvest, pointing out that the area has not received enough attention for a while.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
A number of bleak years for pharmaceutical firm Novo Nordisk’s insulin business, particularly in the US, have been replaced by a bright outlook.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.